NeRRe Therapeutics Archives

Best in Biotech 16 Feb 2022

Top 10 Biotech Companies in Stevenage, UK’s Hidden Life Sciences Gem

These are the top biotech companies based in Stevenage, an English town that has become a life sciences hub that competes with the likes of London, Oxford, and Cambridge. The UK’s life sciences scene is mostly centered around the golden triangle of London, Oxford, and Cambridge. Situated right in the middle of this triangle, the […]

February 16, 2022 - 6 minutesmins - By Clara Rodríguez Fernández

Expert Advice 11 Mar 2020

Why Women’s Health Can Be a Good Investment

Since the Hormone Replacement Therapy market was destroyed almost overnight in 2002 after side effects were reported by researchers, there has been a lot of caution about investing in companies with a focus on women’s health. Mary Kerr, CEO of KaNDy Therapeutics and NeRRe Therapeutics, knows this only too well, but has not let it […]

March 11, 2020 - 13 minutesmins - By Helen Albert

Best in Biotech 21 May 2019

The Top 20 Women in Leading Biotech Roles in Europe

The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […]

May 21, 2019 - 12 minutesmins - By Jonathan Smith

Best in Biotech 8 Mar 2018

Say Hello to the Top 14 Entrepreneurial Women in European Biotech

Today, March 8, is international women’s day. To celebrate the achievements of women we’re revisiting our list of the women that have founded some of the hottest biotechs in Europe. Once upon a time, you would have been hard pushed to find a woman in a senior position at a top biotech – now, they […]

March 8, 2018 - 8 minutesmins - By Alex Dale

News and Trends 26 Jan 2018

New British Spinout May Get Snapped Up by Allergan for $400M

KaNDy Therapeutics, a women’s health spinout helmed by Mary Kerr, is rumored to be in acquisition talks that value the company at $400M (€322M). Details are sparse, but according to a report from Bloomberg, Stevenage-based KaNDy Therapeutics is supposedly in the late stages of a discussion with Allergan about a possible buyout. KaNDy, a recent spinout […]

January 26, 2018 - 1 minutemin - By Evelyn Warner

Interview 9 Nov 2017

Meet the Spin-Out Queen Taking on Neurological Diseases

Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […]

November 9, 2017 - 4 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will focus on the development of a drug with potential to significantly improve the treatment of […]

September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 5 Jan 2017

Investors Jump on Hypersensitivity Peptides from GSK Spinout

Neurokinins are under investigation for a range of conditions from women’s health to pain. NeRRe gets a boost for its programs. Neurotransmitting peptides just got a cash injection from Forbion, Fountain Healthcare Partners, Advent Life Sciences, Novo A/S, and Orbimed. NeRRe Therapeutics, a UK-based spinout of GSK, nailed down a €27M (£23M) Series B round. Helmed by […]

January 5, 2017 - 2 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us